Lowers Novo Nordisk’s Target Stock Price to 875 Danish Krone
January 14, 2025
Source: drugdu
29
Securities Times Network reports that Goldman Sachs has lowered the target stock price for Novo Nordisk to 875 Danish krone (approximately $102.5), but still maintains a "buy" rating. This move is not an isolated case, as both BNP Paribas and Jyske Bank have also reduced their target prices while maintaining an outperform or buy rating. Novo Nordisk's stock price has fluctuated significantly recently, with some investors expressing disappointment over the performance data of its weight loss drugs. Additionally, UK-based Hikma Pharmaceuticals has received FDA approval to launch a generic version of Novo Nordisk's diabetes injection, increasing competitive pressure in the market.
https://finance.eastmoney.com/a/202501133294434240.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 2025 medical device global exhibition summary January 15, 2025
- 2025 Biopharmaceutical global exhibition summary January 15, 2025
- IPO Radar | Losing 1 billion yuan in one year, Maiwei Biotechnology seeks A+H listing, how long can it survive relying on external “blood transfusion”? January 15, 2025
- Johnson&Johnson’s new drug, Edatinib, has been approved for market in China | Medical Early Reference January 15, 2025
- United Imaging Medical, there are big moves in North America January 15, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
